Adrenal Fatigue

Adrenal Fatigue: A Critical and Comprehensive Reference

1. Definition, Nomenclature, and Diagnostic Status

"Adrenal fatigue" is a term used in alternative medicine contexts to suggest that the adrenal glands are exhausted and unable to produce adequate quantities of hormones, primarily cortisol, due to chronic stress or infections. The term was coined in 1998 by chiropractor James Wilson and applied to a collection of mostly non-specific symptoms. In Wilson's 2001 book, Adrenal Fatigue: The 21st Century Stress Syndrome, adrenal fatigue is suggested to develop when the adrenal glands become exhausted due to chronic stress and are thus unable to produce adequate amounts of adrenal hormones to deal with daily events and stresses of life.

There is no scientific basis for the existence of adrenal fatigue as a discrete condition, and the term should not be confused with a number of actual forms of adrenal dysfunction such as adrenal insufficiency or Addison's disease. The term has been used by some doctors, healthcare providers, and the general media to describe an alleged condition caused by chronic exposure to stressful situations, but it has not been recognized by any Endocrinology society, who claim there is no hard evidence for its existence.

A systematic review published in 2016 in BMC Endocrine Disorders (Cadegiani & Kater) concluded that there is no substantiation that "adrenal fatigue" is an actual medical condition. Despite widespread use of the term, only ten citations were found using the exact expression "adrenal fatigue," and none of them performed any testing of the HPA axis; studies that did attempt to correlate the HPA axis with fatigue states used the term "burnout" rather than "adrenal fatigue" to denote adrenal depletion.

In studies to date, proposed methods to assess adrenal fatigue have produced conflicting results, and the methodology for assessing the hypothalamic-pituitary-adrenal (HPA) axis has often been inappropriate. Furthermore, only a minority of studies have actually examined the HPA axis. Current evidence does not support the existence of adrenal fatigue or the usefulness of supplements to support adrenal function.

1.1 HPA Axis Dysregulation as an Alternative Framework

While the "adrenal fatigue" label is not medically recognized, researchers and integrative clinicians have proposed the term HPA axis dysregulation (HPA-D) as a more scientifically grounded framework for describing the cluster of stress-related neuroendocrine disturbances that underlie many of the symptoms attributed to "adrenal fatigue." The hypothalamic-pituitary-adrenal (HPA) axis plays a central role in the body's stress response and is increasingly recognized as a contributor to a range of chronic health conditions; a growing body of research aims to provide an evidence-based overview of HPA axis dysregulation, including its underlying mechanisms, diagnostic approaches, and integrative strategies.

HPA axis dysfunction is a dysregulation of the communication network between the hypothalamus, pituitary gland, and adrenal glands that controls the stress response, cortisol production, energy regulation, immune function, and metabolism. When this system loses its ability to self-regulate after prolonged stress, it produces erratic cortisol patterns that ripple through nearly every organ system in the body.

2. Presenting Symptoms and Body Systems Involved

Proponents of adrenal fatigue state that millions of people have under-active adrenal glands due to repeated stressors, resulting in numerous nonspecific symptoms such as fatigue, insomnia, joint pain, and weight gain, among others. It is said to occur in people who have chronic high stress (mental, emotional, or physical) in their work and/or family life, and is characterized by nonspecific symptoms such as fatigue, sleep disturbances, difficulty coping, body aches, digestive problems, and dependency on caffeine.

Neither the condition nor the symptoms have any stable or recognized definition, which makes systematic clinical evaluation difficult. Much of what is discussed under this heading in functional and integrative medicine literature overlaps with scientific research on HPA axis function and cortisol patterning. Distinctly flattened diurnal cortisol levels have been linked in the scientific literature to chronic fatigue syndrome, burnout, and insomnia.

2.1 The Neuroendocrine Cascade

The HPA axis operates via a well-defined cascade. The paraventricular nucleus (PVN) of the hypothalamus plays a pivotal role by secreting corticotropin-releasing hormone (CRH), the key initiator of the HPA axis cascade, which then stimulates the anterior pituitary to release adrenocorticotropic hormone (ACTH). ACTH in turn stimulates the adrenal cortex to produce cortisol. Cortisol, a key regulator of the stress response, peaks in the early morning to promote wakefulness and gradually declines throughout the day; in contrast, melatonin, which facilitates sleep, peaks at night.

Chronic stress leads to impaired HPA axis feedback, glucocorticoid receptor resistance, and paradoxical cortisol dysregulation, fostering a pro-inflammatory state that promotes cytokine imbalance, weakens protective immune mechanisms, and shifts the immune response toward dysregulation.

Chronic stress states can lead to either over- or under-expression of cortisol, and suppression or overstimulation of the HPA axis. In either situation, the HPA axis is not able to react optimally to a stimulus.

2.2 HPA Dysfunction in Chronic Fatigue Syndrome

Research on Chronic Fatigue Syndrome (CFS), which shares considerable symptom overlap with what is described as adrenal fatigue, has revealed measurable HPA axis abnormalities. HPA axis dysfunction has been found in a high proportion of CFS patients and includes enhanced corticosteroid-induced negative feedback, basal hypocortisolism, attenuated diurnal variation, and a reduced responsivity to challenge. The weight of current evidence supports the presence of mild hypocortisolism, attenuated diurnal variation of cortisol, enhanced negative feedback to the HPA axis, and blunted HPA axis responsiveness in CFS patients. Furthermore, HPA axis changes appear clinically relevant, as they are associated with worse symptoms and/or disability and with poorer outcomes to standard treatments.

Despite this temporal relationship, it is not yet established whether the endocrine dysregulation in CFS is causal, consequent, or an epiphenomenon of the disorder.

3. Contributing and Associated Factors

HPA axis dysfunction is influenced by a complex interplay of internal and external stressors, including chronic psychological stress, dietary imbalances, disrupted circadian rhythms, and environmental exposures.

3.1 Chronic Psychological and Physical Stress

Chronic stress triggers prolonged HPA axis activation, resulting in elevated cortisol levels, which can lead to hippocampal atrophy, synaptic dysfunction, and neuroinflammation. Persistent disruption of homeostatic glucocorticoid circadian rhythmicity due to chronic stress exposure is correlated with the incidence of various pathological conditions including depression, diabetes, and cancer.

Allostatic adaptation — the process by which the body attempts to maintain glucocorticoid homeostasis under chronic stress — results in a physiological cost (allostatic load) that might impair the homeostatic stress-responsive and synchronizing functions of the HPA axis.

3.2 Circadian Rhythm Disruption

Circadian control of the hypothalamus-pituitary-adrenal axis is critical for regulation of hormones involved in the stress response, and dysregulation of the HPA axis is associated with neuropsychiatric disorders. It is therefore important to understand how disruption of the circadian rhythm alters the HPA axis. Animal research using gene knockout models has confirmed that circadian gene disruption directly dysregulates the HPA stress axis.

3.3 Immune System Interactions and Inflammation

Evidence from both human and animal studies associates persistent HPA dysfunction with diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. HPA axis dysregulation under chronic stress constitutes a critical mechanistic link between psychological stress and autoimmune disease.

3.4 Genetic and Epigenetic Factors

A putative causal role for genetic profile, childhood trauma, and oxidative stress has been considered in HPA axis dysregulation. The impact of sex is demonstrated by the increased frequency of HPA axis dysregulation in females.

Deficient glucocorticoid receptor (GR) feedback is implicated in depression, and several genetic and environmental factors have been associated with this impaired feedback.

4. Nutrients Studied in Relation to Adrenal Function and HPA Dysregulation

The following section presents nutrients discussed in the scientific and traditional health literature in relation to adrenal and HPA axis function. Each nutrient's traditional use (where applicable) is separated from the available scientific evidence, and the strength of that evidence is characterized plainly.

4.1 Vitamin C (Ascorbic Acid)

Physiological role: In mammals, the stress response is characterized by activation of the HPA axis and sympathoadrenal system (SAS) as well as the increased synthesis and secretion of vitamin C. Cortisol, catecholamines, and vitamin C act synergistically to increase hemodynamic reserve, maintain immune function, and protect the host against excessive oxidant injury.

Observations of very high levels of vitamin C in the adrenal gland, as well as its release in response to adrenocorticotrophic hormone (ACTH), provide evidence that vitamin C plays a role in the stress response. When the HPA axis is stimulated, the concentration of vitamin C in the blood increases.

The adrenal glands contain some of the highest vitamin C concentrations in the entire body. During periods of stress, these glands rapidly deplete their vitamin C stores to synthesize cortisol and catecholamines.

Scientific evidence: Vitamin C is necessary for cortisol synthesis as it is a co-factor for enzymes present in the adrenal glands. Animal studies suggest that, while vitamin C is required for cortisol production, an optimal vitamin C level can reduce the amount of cortisol released in response to stress. In clinical trials, supplementation with vitamin C was effective in reducing anxiety, decreasing stress levels, improving recovery from mental stress, boosting mood, and improving blood pressure levels in stressed participants. These findings are primarily from small clinical trials and animal studies; high-quality, large-scale RCTs specifically targeting HPA axis normalization are limited.

4.2 Pantothenic Acid (Vitamin B5)

Physiological role: Vitamin B5 (pantothenic acid) is the direct precursor to coenzyme A (CoA), which the body uses to synthesize steroid hormones including cortisol. Without adequate B5, the entire hormone production pathway slows down. Deficiency is rare in people eating a varied diet, but stress may increase demand for B vitamins across the board.

Vitamin B5 is a key component of coenzyme A, which drives steroidogenesis — the process of producing hormones from cholesterol.

Scientific evidence: Animal research has found that pantothenic acid supplementation stimulates the ability of adrenal cells in male rats to secrete corticosterone, a glucocorticoid involved in regulation of energy, immune reactions, and stress responses. Direct human clinical trial evidence specifically examining pantothenic acid supplementation and HPA axis function is limited; much of the evidence base consists of animal studies and mechanistic/biochemical data.

4.3 Magnesium

Physiological role: Magnesium decreases the release of ACTH and modulates adrenocortical sensitivity to this hormone. It is presumed that magnesium induces a suppression of HPA axis activity, at least partially, through antagonism of angiotensin II effects.

Scientific evidence: Preclinical and some clinical studies suggest a relationship between perturbation in magnesium homeostasis and pathological anxiety, although the underlying mechanisms remain largely unknown. Evidence indicates that magnesium modulates the hypothalamic-pituitary-adrenal (HPA) axis. In a preclinical study, magnesium deficiency caused an increase in the transcription of corticotropin-releasing hormone (CRH) in the paraventricular hypothalamic nucleus (PVN), which coincided with elevated ACTH plasma levels, pointing to an enhanced set-point of the HPA axis. Much of this evidence is from animal models; robust human RCTs focused specifically on magnesium's effect on adrenal-related outcomes remain sparse.

4.4 Phosphatidylserine

Scientific evidence: Supplementation with a phosphatidylserine and phosphatidylserine/phosphatidic acid complex (PAS) has been observed to normalize stress-induced dysregulations of the hypothalamus-pituitary-adrenal axis. Prolonged stress first induces a hyper-activation of the HPAA, which can then be followed by a state of hypo-activation.

In a double-blind, placebo-controlled study of 75 chronically stressed healthy male volunteers, supplementation with 400 mg phosphatidylserine plus 400 mg phosphatidic acid per day for 42 days was effective in normalizing the ACTH (p = 0.010), salivary (p = 0.043), and serum cortisol responses (p = 0.035) to an acute psychosocial stress test in chronically high-stressed subjects — but not in low-stressed subjects. Evidence is promising but limited to small sample sizes, short durations, and specific (male, stressed) populations. Generalizability remains to be established.

5. Herbs and Botanical Ingredients

5.1 Ashwagandha (Withania somnifera)

Traditional use: Ashwagandha (Withania somnifera) is an adaptogenic herb used traditionally in Ayurvedic medicine to prevent and treat psychosomatic disorders. Its historical use spans thousands of years in the Indian subcontinent as a general tonic for physical and mental vitality.

Scientific evidence — overview: Nine randomized controlled trials involving 558 patients were included in a 2024 meta-analysis. The findings showed a significant effect of ashwagandha formulations on the Perceived Stress Scale (PSS) (MD = −4.72, 95% CI [−8.45 to −0.99]), Hamilton Anxiety Scale (MD = −2.19, 95% CI [−3.83 to −0.55]), and serum cortisol levels (MD = −2.58, 95% CI [−4.99 to −0.16]) compared to placebo.

A separate 2025 meta-analysis (15 RCTs, n = 873) showed a significant effect in reducing stress (PSS mean difference = −4.88, 95% CI: −7.84 to −1.91, p = 0.0013) and cortisol levels (mean difference = −2.3626, 95% CI: −3.2622 to −1.4629, p < 0.0001) at 8 weeks of treatment.

Specific trial: In a 60-day, randomized, double-blind, placebo-controlled study, 60 healthy stressed adults were randomly allocated to take either a placebo or 240 mg of a standardized ashwagandha extract (Shoden) once daily. Ashwagandha supplementation was associated with a statistically significant reduction in the Hamilton Anxiety Rating Scale (HAM-A) (p = .040), and with greater reductions in morning cortisol (p < .001) and DHEA-S (p = .004) compared with placebo. These findings suggest that ashwagandha's stress-relieving effects may occur via its moderating effect on the hypothalamus-pituitary-adrenal axis; however, further investigation utilizing larger sample sizes, diverse clinical and cultural populations, and varying treatment dosages is needed.

Evidence limitations: Current evidence supporting the efficacy and safety of ashwagandha root extract on cognitive functions or stress is from small studies. The main limitation of these trials is their small sample sizes, necessitating a need for larger trials. Doses in included studies ranged from 125–600 mg daily for 30–90 days, with both root-alone and root-and-leaf combined formulations used, complicating direct comparisons.

5.2 Rhodiola (Rhodiola rosea)

Traditional use: Rhodiola rosea, also known as arctic root, roseroot, and golden root, has been used as a traditional folk remedy in Europe and a traditional Chinese medicine in Asia for enhancing endurance, work performance, fertility, and longevity, and for reducing fatigue, depression, anemia, and altitude sickness.

Regulatory recognition: Based on its long-term use in traditional medicine and numerous scientific studies, in 2011 the European Medicines Agency (EMA) herbal monograph on Rhodiola rosea L. rhizoma et radix (EMA/HMPC/232091/2011) approved its traditional use as an adaptogen for the temporary relief of symptoms associated with stress, such as fatigue, exhaustion, and a general sensation of weakness. The final report of the agency concluded that the long-standing use, as well as the outcome of the clinical trials, supported the plausibility of the use of R. rosea's herbal preparation in the proposed indication.

Scientific evidence — mechanisms: Data from animal and human studies suggest that R. rosea may have adaptogenic properties via its modulation of central stress response mechanisms through effects on central neurotransmission and neuroendocrine function. Specifically, R. rosea appears to have a positive impact on HPA axis activity, which in turn modulates the central immune-response system; this action is thought to play a key role in modulating stress and the body's ability to adapt to it.

Salidroside, a phenylpropanoid glycoside, is thought to be the main active constituent. It has anti-inflammatory, anti-oxidative, anti-apoptotic, and neuroprotective properties, and can regulate the hypothalamus-pituitary-adrenal (HPA) axis.

Scientific evidence — clinical trials: More than 30 publications on the clinical efficacy of various Rhodiola rosea preparations can be found in the PubMed database. The majority of these studies are of varying methodological rigor and concern cognitive functions and mental performance under fatigue. Rhodiola rosea, in particular, significantly reduced symptoms of fatigue and improved attention after four weeks of repeated administration. It was suggested that the inhibitory effect of Rhodiola rosea on the increased basal level of salivary cortisol results in an improvement of cognitive function, in line with other studies demonstrating that optimal corticosteroid levels are a requirement for efficient cognitive function.

Evidence strength: The EMA traditional-use approval and a substantial body of clinical trial literature place Rhodiola rosea among the better-studied adaptogens for fatigue and stress. However, methodological heterogeneity across trials — varying extract standardization, dosages, outcome measures, and populations — limits firm conclusions.

5.3 Licorice Root (Glycyrrhiza glabra)

Traditional use: Glycyrrhiza glabra and Glycyrrhiza uralensis are among the most versatile, popular, and widely used of all medicinal plants. Glycyrrhiza glabra, in the Fabaceae family, was named "sweet root" by Dioscorides (a Greek physician), and it was widely used in Europe during the Middle Ages and Renaissance. Traditional Chinese medicine has long recognized this plant's value as a "guide drug" that enhances other herbs' effects.

Scientific evidence — mechanism: Glycyrrhizin, glycyrrhizic acid, and glycyrrhetinic acid may influence the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), which is responsible for breaking down cortisol into its inactive form. One of the most studied compounds in Glycyrrhiza is the steroidal saponin glycyrrhizin, which acts directly on the adrenal cortex and increases blood corticoids in patients with suppressed pituitary adrenocorticotropin (ACTH). Glycyrrhiza supports adrenal function in part by affecting cortisol-metabolizing dehydrogenase enzymes, as evidenced by increased blood levels of cortisol and decreased urinary excretion demonstrated with both animal and human studies. Inhibition of these enzymes will prolong the life of cortisol in general circulation and may support a weak adrenal gland by boosting tissue cortisol levels when adrenal output is insufficient.

Evidence strength: Mechanistic evidence from animal and human laboratory investigations supports the 11β-HSD2 inhibiting action of glycyrrhizin. However, large-scale clinical trials investigating licorice root specifically for HPA dysregulation-related outcomes are lacking. The evidence base is primarily biochemical and pharmacological rather than from long-duration RCTs.

5.4 Holy Basil / Tulsi (Ocimum tenuiflorum)

Traditional use: Ocimum tenuiflorum, also known as Ocimum sanctum, Holy Basil, or Tulsi, is an aromatic plant native to south-east Asia that has been commonly used in Indian traditional medicine. In Ayurveda, it is referred to as "the elixir of life" and is believed to promote longevity.

Scientific evidence: Ocimum tenuiflorum has been demonstrated through in vitro, animal, and clinical trials to have anti-stress, adaptogenic, antioxidant, analgesic, anti-asthmatic, and anti-inflammatory properties. These beneficial effects are believed to be derived from its biochemically active constituents including eugenol, carvacrol, ursolic acid, β-caryophyllene, and rosmarinic acid. The evidence of the therapeutic efficacy of Ocimum tenuiflorum was found to be favorable in a 2017 systematic review, particularly as an adaptogen with a role in helping address psychological, physiological, immunological, and metabolic stresses of modern living; however, further robust research was called for. As an anxiolytic agent, clinical trials are limited, although anti-stress benefits have been identified in adults at daily doses of 1,000–1,200 mg. Evidence is preliminary and requires larger, better-controlled trials.

5.5 Adaptogens: General Considerations and the Evidence Base

The most convincing evidence for the efficacy of adaptogens was found in studies related to neuroprotective effects, effects on cognitive functions and mental performance in fatigue, and efficacy in asthenia and depression. The evidence points to adaptogens potentially being beneficial for neurodegenerative disorders.

Key active constituents of adaptogens such as rhodiola operate through several converging pharmacological mechanisms. Unlike direct cortisol suppressants or adrenal stimulants, their effects appear to modulate the stress response system at multiple levels simultaneously — explaining their capacity to reduce fatigue while supporting rather than suppressing alertness.

6. Dietary and Lifestyle Factors

6.1 Dietary Patterns

A comprehensive review of peer-reviewed literature examining multifactorial contributors to HPA axis dysfunction identified sources of evidence covering psychological stress, dietary and lifestyle factors, genetic and epigenetic influences, immune system interactions, gut health, inflammation, environmental toxins, and hormonal imbalances.

Within this framework, dietary patterns are discussed as modulators of HPA axis reactivity through several proposed pathways, including glycaemic regulation, micronutrient status, and the gut-brain axis. HPA axis dysfunction is influenced by dietary imbalances alongside chronic psychological stress, disrupted circadian rhythms, and environmental exposures.

6.2 Sleep and Circadian Rhythm

The hypothalamus releases CRH in response to various stimuli including stress, exercise, disease, blood cortisol levels, and circadian rhythm. After waking, cortisol levels rise swiftly in healthy people and peak in 30 to 45 minutes. Cortisol progressively falls over the day and rises again in the late afternoon, then begins to decline in the late evening. This pattern corresponds to the rest-activity cycle of the organism.

Circadian control of the hypothalamus-pituitary-adrenal axis is critical for regulation of hormones involved in the stress response. Disruption of this rhythm — through irregular sleep schedules, shift work, or chronic light exposure at night — is therefore an important contributing factor to HPA dysregulation as understood by the peer-reviewed literature.

6.3 Exercise

Moderate-intensity physical activity is discussed in the integrative medicine literature as supporting HPA axis homeostasis. The 2025 American Journal of Medicine review on HPA axis dysfunction cited studies examining endocrine responses of the stress system to different types of exercise, noting that the endocrine responses of the stress system differ based on the type of exercise performed. Evidence from this and related literature suggests that moderate aerobic exercise supports basal HPA modulation, while overtraining or excessive high-intensity exercise without adequate recovery may exacerbate HPA axis stress signalling.

6.4 Psychological Stress Reduction Practices

The American Journal of Medicine 2025 review of integrative approaches to HPA axis dysfunction identified yoga and mindfulness-based practices as topics of research interest, citing findings that yoga practice improves executive function by attenuating stress levels, consistent with a broader literature on mind-body interventions and HPA axis modulation. Evidence in this area is promising but heterogeneous in design and outcome measurement.

7. The Supplement Industry and "Adrenal Support" Products

The concept of adrenal fatigue has given rise to an industry of dietary supplements marketed to treat the supposed condition. These supplements are largely unregulated in the U.S.; they are ineffective and costly; and in some cases may be dangerous.

Affected people are encouraged to self-diagnose adrenal fatigue based on symptoms using scoring systems available on internet websites, a practice that endocrinologists and mainstream medical bodies have consistently cautioned against. Adrenal fatigue is not recognized by the Endocrine Society or any other endocrinology society, but adrenal insufficiency is.

Within this context, individual nutrients and botanicals reviewed in this article — vitamin C, pantothenic acid, magnesium, ashwagandha, and rhodiola — have research-based rationale for their roles in HPA axis physiology and stress biology, distinct from the unvalidated "adrenal fatigue" marketing framework within which they are often commercially presented.

References

• Cadegiani FA, Kater CE. "Adrenal fatigue does not exist: a systematic review." BMC Endocrine Disorders. 2016;16(1):48. PMC.
• Ross IL, Jones J, Blockman M. "We are tired of 'adrenal fatigue'." South African Medical Journal. 2018;108(9):724–725. PubMed.
• McDermott MT. "Pseudo-endocrine Disorders: Recognition, Management, and Action." Journal of the Endocrine Society. 2024;9(1):bvae226. PMC.
• An Integrative Approach to HPA Axis Dysfunction: From Recognition to Recovery. The American Journal of Medicine. 2025.
• Tomas C, Newton J, Watson S. "A Review of Hypothalamic-Pituitary-Adrenal Axis Function in Chronic Fatigue Syndrome." ISRN Neuroscience. 2013. PMC.
• Cleare AJ. "Hypothalamic–pituitary–adrenal axis dysfunction in chronic fatigue syndrome." Nature Reviews Endocrinology. 2012.
• Systematic review and meta-analysis: Effects of Ashwagandha Supplements on Cortisol, Stress, and Anxiety Levels in Adults. BJPsych Open / PMC. 2025.
• Pratte MA et al. "Effects of Ashwagandha (Withania Somnifera) on stress and anxiety: A systematic review and meta-analysis." Journal of Affective Disorders. 2024. PubMed.
• Lopresti AL et al. "An investigation into the stress-relieving and pharmacological actions of an ashwagandha extract: A randomized, double-blind, placebo-controlled study." Medicine. 2019. PMC.
• Kasparaviciene G et al. "The Effectiveness of Rhodiola rosea L. Preparations in Alleviating Various Aspects of Life-Stress Symptoms and Stress-Induced Conditions." Pharmaceutics. 2022. PMC.
• Panossian A, Wikman G. "Effects of Adaptogens on the Central Nervous System and the Molecular Mechanisms Associated with Their Stress-Protective Activity." Pharmaceuticals. 2010. PMC.
• Mao JJ et al. "Rhodiola rosea therapy for major depressive disorder: a study protocol for a randomized, double-blind, placebo-controlled trial." Journal of Clinical Trials. 2015. PMC.
• Hellhammer J et al. "A soy-based phosphatidylserine/phosphatidic acid complex normalizes the stress reactivity of hypothalamus-pituitary-adrenal-axis in chronically stressed male subjects." Nutrition Journal. 2014. PMC.
• Sartori SB et al. "Magnesium deficiency induces anxiety and HPA axis dysregulation: Modulation by therapeutic drug treatment." Neuropharmacology. 2012. PMC.
• Grases G et al. "Magnesium and stress." In: Vink R, Nechifor M, eds. Magnesium in the Central Nervous System. University of Adelaide Press. NCBI Bookshelf.
• Marik PE. "Vitamin C: an essential 'stress hormone' during sepsis." Journal of Thoracic Disease. 2020. PMC.
• Lopresti AL et al. "A randomized, double-blind, placebo-controlled trial investigating the effects of an Ocimum tenuiflorum (Holy Basil) extract on stress, mood, and sleep in adults experiencing stress." Evidence-Based Complementary and Alternative Medicine. 2022. PMC.
• Hypothalamic-Pituitary-Adrenal (HPA) Axis: Unveiling the Potential Mechanisms Involved in Stress-Induced Alzheimer's Disease and Depression. PMC. 2024.
• Gudmand-Høyer J et al. "Allostatic adaptation and personalized physiological trade-offs in the circadian regulation of the HPA axis." Scientific Reports. 2019. PMC.
• Chronic Stress and Autoimmunity: The Role of HPA Axis and Cortisol Dysregulation. PMC. 2025.
• Hypothalamic–Pituitary–Adrenal Axis Dysfunction in People With Cancer: A Systematic Review. PMC. 2024.
• Adrenal fatigue. Wikipedia (for historical/nomenclature context only).